Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study

Simone Garcovich; Alberto Ruggeri; Magda D'Agostino; Fausta Ardito; Clara De Simone; Giovanni Delogu; G. Fadda

doi:10.1111/j.1468-3083.2011.04220.x

Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study

Simone Garcovich, Alberto Ruggeri, Magda D'Agostino, Fausta Ardito, Clara De Simone, Giovanni Delogu, G. Fadda

Risultato della ricerca: Contributo in rivista › Articolo in rivista

41 Citazioni (Scopus)

Abstract

Psoriasis patients who are treated with tumour necrosis factor (TNF)-alpha antagonists are at increased risk of reactivation of latent tuberculosis infection (LTBI) and should be adequately screened and monitored during active treatment.

Lingua originale	English
pagine (da-a)	1572-1576
Numero di pagine	5
Rivista	Journal of the European Academy of Dermatology and Venereology
Volume	26
DOI	https://doi.org/10.1111/j.1468-3083.2011.04220.x
Stato di pubblicazione	Pubblicato - 2012

Keywords

tbc

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1111/j.1468-3083.2011.04220.x

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Garcovich, S., Ruggeri, A., D'Agostino, M., Ardito, F., De Simone, C., Delogu, G., & Fadda, G. (2012). Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. Journal of the European Academy of Dermatology and Venereology, 26, 1572-1576. https://doi.org/10.1111/j.1468-3083.2011.04220.x

@article{3468823d18dc47839a4f43f2676ee3c9,

title = "Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study",

abstract = "Psoriasis patients who are treated with tumour necrosis factor (TNF)-alpha antagonists are at increased risk of reactivation of latent tuberculosis infection (LTBI) and should be adequately screened and monitored during active treatment.",

keywords = "tbc, tbc",

author = "Simone Garcovich and Alberto Ruggeri and Magda D'Agostino and Fausta Ardito and {De Simone}, Clara and Giovanni Delogu and G. Fadda",

year = "2012",

doi = "10.1111/j.1468-3083.2011.04220.x",

language = "English",

volume = "26",

pages = "1572--1576",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "1468-3083",

publisher = "John Wiley and Sons Inc.",

}

Garcovich, S, Ruggeri, A, D'Agostino, M, Ardito, F, De Simone, C , Delogu, G & Fadda, G 2012, 'Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study', Journal of the European Academy of Dermatology and Venereology, vol. 26, pagg. 1572-1576. https://doi.org/10.1111/j.1468-3083.2011.04220.x

Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. / Garcovich, Simone; Ruggeri, Alberto; D'Agostino, Magda et al.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 26, 2012, pag. 1572-1576.

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study

AU - Garcovich, Simone

AU - Ruggeri, Alberto

AU - D'Agostino, Magda

AU - Ardito, Fausta

AU - De Simone, Clara

AU - Delogu, Giovanni

AU - Fadda, G.

PY - 2012

Y1 - 2012

N2 - Psoriasis patients who are treated with tumour necrosis factor (TNF)-alpha antagonists are at increased risk of reactivation of latent tuberculosis infection (LTBI) and should be adequately screened and monitored during active treatment.

AB - Psoriasis patients who are treated with tumour necrosis factor (TNF)-alpha antagonists are at increased risk of reactivation of latent tuberculosis infection (LTBI) and should be adequately screened and monitored during active treatment.

KW - tbc

UR - http://hdl.handle.net/10807/40734

U2 - 10.1111/j.1468-3083.2011.04220.x

DO - 10.1111/j.1468-3083.2011.04220.x

M3 - Article

SN - 1468-3083

VL - 26

SP - 1572

EP - 1576

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

ER -

Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo